Resources Repository
-
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Mathematical Models | Chronic Disease/Risk | Europe -
ReviewPublication 2023Economic & Humanistic Burden of Osteoarthritis: Systematic Review of Large Sample Studies
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported …
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported by large sample studies since 2016. Medline (via Ovid) and Embase were searched using an updated strategy based on a previous review. Studies with a sample size ≥1000 that measured direct or indirect costs or health-related quality of life (HRQL) of OA were included. Pairs of reviewers independently screened studies, and an arbitrator resolved discrepancies. The Kappa value for agreement…
Cost-Effectiveness Analysis | Health/Medicine | Preferences/Values | Evidence Synthesis | Chronic Disease/Risk | Global -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Technology Assessment | Health/Medicine | Preferences/Values | Evidence Synthesis | Policy/Regulation -
ReviewPublication 2021Review of Web-Based Tools for Value-of-Information Analysis
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial …
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial design, and provide information for decisions about reimbursement. The authors review existing web-based tools to facilitate VOI calculations. These include Sheffield Accelerated Value of Information (SAVI), the web interface to the BCEA (Bayesian Cost-Effectiveness Analysis) R package (BCEAweb), Rapid Assessment of Need for Evidence (RANE), and Value of Information for Cardiovascular Trials and Other Comparative Research (VICTOR).
Cost-Effectiveness Analysis | Health/Medicine | Decision Theory | Priority Setting/Ethics | Value of Information | Economics/Finance -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Health/Medicine | Infectious Diseases | Economics/Finance | Global -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | North America -
ReviewPublication 2022Multicriteria Decision Analysis to Support Decision Making in Healthcare
This study reviews the application of multicriteria decision analysis (MCDA) in healthcare, aiming to clarify …
This study reviews the application of multicriteria decision analysis (MCDA) in healthcare, aiming to clarify its use across various decision-making contexts. The authors updated a 2013 systematic review by searching Embase, MEDLINE, and Google Scholar for English-language MCDA studies published from August 2013 to November 2020. Additionally, grey literature from January 1990 to November 2020 was reviewed via the Trip Medical Database and Google. Information on decision context, criteria, methods, stakeholders, and sensitivity analyses was…
Decision Analysis | Health/Medicine | Priority Setting/Ethics | Evidence Synthesis -
ReportPublication 2022Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
The article introduces the CHEERS 2022 statement, an updated set of guidelines for reporting health …
The article introduces the CHEERS 2022 statement, an updated set of guidelines for reporting health economic evaluations. Health economic evaluations compare alternative actions in terms of costs and consequences. The original CHEERS statement, published in 2013, aimed to make these evaluations clear, interpretable, and useful for decision-making by providing a standardized reporting format. Methods involved reviewing advancements in health economic evaluation methods and the need for inclusive stakeholder engagement, including patients and the public. The…
Cost-Effectiveness Analysis | Health/Medicine -
ReviewPublication 2021Users' Guide to Medical Decision Analysis
The article emphasizes the significance of decision analysis in aiding clinicians to make evidence-based choices …
The article emphasizes the significance of decision analysis in aiding clinicians to make evidence-based choices between testing and treatment strategies. While clinicians may not conduct decision analyses themselves, they often rely on publications or guidelines derived from them. The review outlines the structure of a decision tree and equips clinicians with the skills to critically evaluate decision analyses and implement their findings in medical decision-making. It highlights two critical judgments clinicians can make: first, assessing…
Decision Analysis | Health/Medicine | Clinical Care